

CLINICO-DEMOGRAPHIC AND RISK CHARACTERISTICS OF WOMEN PATIENTS OF REPRODUCTIVE AGE AT THE DE LA SALLE UNIVERSITY MEDICAL CENTER (DLS-HSI) AND THE MORPHO-PHYSIOLOGICAL AND ANTIFUNGAL SENSITIVITY PROPERTIES OF THE CANDIDA SPECIES ISOLATED

> A Research Paper Presented to The College of Science Graduate Studies De La Salle University – Dasmariñas

In Partial Fulfilment of the Requirements for the degree of Master of Science in Biology

LLYRHA MAE E. MAGHARI

MAY 2009

ABSTRACT

Vulvo-vaginal candidiasis (VVC) is a common universal problem encountered that affects a large fraction of women in a population. This study was conducted to determine the relationship of clinico-demographic and risk characteristics of women patients of reproductive age at the De La Salle University Medical Center to the prevalence of *Candida* species, and to evaluate the *in-vitro* sensitivity of the isolated *Candida* species to six commonly used antifungal agents.

Preliminary isolation of *Candida* species was done using the Brain Heart Infusion Broth (BHIB) and subcultured on Saboraud Dextrose Agar (SDA). Gram-staining was also performed to ensure that the collected species were yeasts. Presumptive test of the isolates was done using the CHROMagar *Candida*. Identified yeast isolates were tested for Germ Tube and Chlamydospore formation to confirm the presence of *C. albicans* while API *Candida* was used to identify the *Candida* species. Sensitivity test was done using the six common antifungal drugs. Frequency, ranking and chi-square tests were performed.

Of the 96 clinical samples, 54 (56.25%) developed green colonies which are characteristic of C. *albicans*, 33 had (34.37%) pink to violet colonies distinctive for *C. krusei*, six (6.25%) had cream-colored colonies the characterisctic of *C. parapsilosis*, and only three (3.12%) had dark blue colonies for *C. tropicalis*.

Representative *Candida* isolates developed color reactions to different sugars, and enzymes in API *Candida*. *C. albicans* were positive for germ tube and chlamydospores.

From a total of 86 respondents, less than one third (30.23 %, 26) were from the out-patient charity department and 69.77 %, 60 came from the out-patient private physician's clinic. Out of the total respondents, the prevalence of *Candida* species were 32 (33.33%) out of the total population were 18 (56.25%) belonged *to C. albicans*, 11 (34.37%) *C. krusei*, two (6.25%) *C. parapsilosis* and one (3.12%) *C. tropicalis.*

Among the patients who are symptomatic and asymptomatic for candidiasis, thirty two (37.2%) out of 86 patients were identified positive for the presence of *Candida species*. Respondents between 41 and 45 years old had the highest frequency of *Candida* infection (9, 28.12%). Majority of the respondents positive for candidiasis were married, and the highest frequency of occurrence of *C. albicans was* found among women with one to two children.

Out of 32 respondents, two (6.25%) had sexual contact with someone having candidiasis. *Candida* species were isolated from both of

respondents. *C. krusei* were isolated from patients who had sexual contact with the same sex. A total of three (9.37%) patients had multiple sex partners. There were 11 (34.37%) *Candida species* isolated from patients with history of candidiasis in the family. Based on actual contact with the disease, 19 (59.37%) were positive for *Candida* species. Majority of patients who were suffering from dysmenorrhea during menstruation harbored *Candida* species. More than 50% of the patients who did not use contraceptive methods harbored more *Candida* isolates than those who adopted contraceptive methods.

Vaginal and labial itchiness and abnormal discharges showed the highest distribution for *Candida* species among the manifestations of VVC.

Antifungal susceptibility testing revealed that eighty (83.33%) out of the 96 *Candida* species isolates were susceptible to amphotericin-B, 38 (39.58%) to Grisefulvin, 72 (75.00%) to Sporonox, 21 (21.88%) to Nizoral, 15 (15.63%) to Diflucan and 78 (81.25%) to Nystatin.

C. albicans is the most prevalent species associated to VVC. In relation to this, women between the age of 36-40 and 41-45 who are married have the highest risk of having such infection. Antifungal prescription should be only given once the proper identification of the *Candida* species has been performed. Improperly prescribed antifungal agents may lead to drug resistance.



TABLE OF CONTENTS

		PAGE
TITLE PAGE	E	1
ABSTRACT		2
APPROVAL	SHEET	4
ACKNOWLE	DGMENT	5
TABLE OF C	CONTENTS	10
LIST OF TAI	BLES	14
LIST OF FIG	BURES	17
LIST OF AP	PENDICES	19
LIST Of APF	PENDICES TABLES	21
LIST OF AP	PENDIX FIGURES	24
CHAPTERS		
Ι.	INTRODUCTION	25
	Objectives of the Study	28
	Scope and Limitation of the Study	29
	Significance of the Study	30
П.	REVIEW OF RELATED LITERATURE	32
	Candida Species	32
	Macroscopic and Microscopic Features of <i>Candida</i> species	34

Page 10 of 213



	Vulvo-vaginal Candidiasis (VVC)	35
	Risk Factors of Vulvo-vaginal Candidiasis	36
	Treatment for Vulvo-vaginal Candidiasis	38
	Clinico-demographic Characteristic of Women	40
	Culture Media	41
	API Candida	42
	Local Studies on Vulvo-vaginal Candidiasis	42
III.	METHODOLOGY	44
	Selection and Classification of Patients	44
	Ethical Considerations	45
	Collection of Specimens	45
	Isolation of Candida Species	46
	Microscopic Identification of <i>Candida</i> Isolates and Colony Morphology Examination	47
	Flow Chart in Data Gathering and Specimen collection	48
	Growth on CHROMagar TM Candida	50
	API Candida	51
	Antifungal Drug Susceptibility Testing	51
	Statistical Analysis	53
IV.	RESULTS AND DISCUSSION	54



۷.

Clinico-Demographic Characteristics of the Respondents	54
Clinical History of the Respondents	56
Risk Characteristics of the Patients	63
Manifestation of VVC Among the Women Respondents	64
Colony and Morphological Characteristics of the Presumptive <i>Candida</i> Isolates	66
Colony characteristics of <i>Candida</i> species on CHROMagar	75
Biochemical reaction of the isolated <i>Candida</i> species to API <i>Candida</i>	76
Prevalence of Candida species	81
Prevalence of <i>Candida</i> species among patient Symptomatic and Asymptomatic for Candidiasis	83
Social History	93
Antibiogram of Candida species Isolates	100
Susceptibility Profile	100
Intermediate Resistance Profile	105
Resistance Profile	106
SUMMARY CONCLUSIONS AND RECOMMENDATIONS	110
Summary	110
Conclusions	118



LIST OF TABLES		
TAB	LE	PAGE
1	Antifungals, their disk potencies and zone of inhibition	52
2	Demographic characteristics of the women respondents (n=86) from De La Salle University Medical Center tested for colonization of <i>Candida</i> species.	55
3	Clinical characteristics of the women respondents (n=86) from De La Salle University Medical Center in relation to vulvo-vaginal candidiasis (VVC).	57
4	Pregnancy record of the respondents from De La Salle University Medical Center (n=86).	59
5	Menstrual history of the patients from De La Salle University Medical Center in response to vulvo-vaginal candidiasis (n=86).	61
6	Contraceptive methods adopted by the respondents from De La Salle University Medical Center (n=86).	63
7	Risk characteristic of reproductive age women from De La Salle University-Medical Center in relation to vulvo-vaginal candidiasis (n=86).	64
8	Frequency of manifestations of vulvo-vaginal candidia exhibited by women from De La Salle University Medie Center of reproductive age (n=86).	sis cal 65
9	Cultural and morphological characteristics of the <i>Candida</i> species isolated from the patients from De La Salle University Medical Center (n=32) grown on Sabouraud Dextrose Agar,	
		Page 14 of 213

		Page 15 of 213
21	Frequency distribution of Candida species among	
20	Frequency distribution of <i>Candida</i> species according to menstrual history of the women (n=32).	96
19	<i>Candida</i> species isolated from patients with social history (n=32).	95
18	Distribution of <i>Candida</i> species among the respondents with clinical presentation related to VVC (n=32).	93
17	Different species of <i>Candida</i> identified in patients from different address (n=32).	91
16	Distribution of <i>Candida</i> species within groups of women with or without siblings (n=32).	90
15	Distribution of <i>Candida</i> species within the civil status of the reproductive age women from De La Salle University Medical Center (n=32).	89
14	Distribution of <i>Candida</i> species by the age group patients of De La Salle University Medical Center (n=32).	86
13	Prevalence of <i>Candida</i> species among patients symptomatic and asymptomatic for Candidiasis (n=32).	85
12	Prevalence of <i>Candida</i> species among patients of De La Salle University Medical Center (n=32).	83
11	Color reactions of the different <i>Candida</i> species to enzymes used in API <i>Candida</i> .	79
10.	Color reactions of the different <i>Candida</i> species to sugars used in API <i>Candida.</i>	79
	Cornmeal Agar and CHROMagar Candida after 48 hours of incubation	68

	patients who used contraceptive methods (n=32).	98
22	Frequency of <i>Candida</i> species among patients with VVC (n=32).	99
23	Susceptibility Profile of <i>Candida</i> isolates to six anti-fungal drugs.	105
24	Intermediate resistance profile of the <i>Candida</i> isolates to six antifungal drugs.	106
25		108
		Page 16 of 213

LIST OF FIGURES		
FIGUI	RE	PAGE
1	Growth and colony characteristics of <i>Candida</i> species isolated from patient of De La Salle University Medical Center (A) C. <i>albicans</i> (PV1), (B) <i>C. krusei</i> (PV10) (C) <i>C. parapsilosis</i> (PV39), (D) <i>C. tropicalis</i> (PV3) on Sabouraud Dextrose Agar after 48 hours of incubation at 37°C.	69
2	Morphological characteristics of the Gram stained <i>Candida</i> Isolates grown on Sabouraud Dextrose Agar at 35 °C to 37° C after 24 hours of incubation (A) <i>C. albicans</i> (PU1), (B) <i>C. Krusei</i> (PU10), (C) <i>C. parapsilosis</i> (PU39), (D) <i>C. tropicalis</i> (PU3) viewed under the O.I.O. (1000X).	72
3	Germ tube formation by the isolate (<i>Candida albicans</i> Isolated from: (A) and (B) vaginal wall specimen (C) endocervical specimen and (D) urine sample of Reproductive aged woman using Lactophenol Cotton Blue stained and viewed under the H.P.O. (400X).	^{;)} 73
4	Chlamydospores formation of Candida albicans in Corn Meal Agar at 35 °C-37° C at 24 hours incubatio viewed under H.P.O. (400X).	n 74
5	Colony characteristics of <i>Candida</i> species (A) <i>C. albicans</i> (PE1), (B) <i>C. krusei</i> (PE10), (C) <i>C. parapsilosis</i> (PE40) (D) <i>C. tropicalis</i> (PE3) on CHROMagar <i>Candida</i> .	77
6	Biochemical reactions of the isolated <i>Candida</i> species to API <i>Candida</i> (A) <i>C. albicans</i> (B) <i>C. krusei</i> (C) <i>C. parapsilosis</i> (D) <i>C. tropicalis.</i>	s 80
7	Sensitivity of <i>Candida</i> species to six antifungal agents (A) <i>C. albicans</i> (B)	
		Page 17 of 213





LIST OF APPENDICES

APPENDIX		PAGE
A	Letter to the Vice-Chancellor for Hospital Operations	137
В	Certification from the English Editor	138
С	Certification from the Statistician	139
D	Certification from the Bioethics Committee	140
E	Questioners	141
F :	Written Informed Consent	145
G	Informed Consent	152
н	Gynecologic Cytology Request Form For Papaniculauo Smear	154
1	Serum Germ Tube Test and Interpretation Of Result	156
12	Germ Tube Test Results	157
J	Yeast Morphology Test Procedure and Interpretation of Result (Chlamydospores)	163
J2	Chlamydospores Results	164
J3	Chlamydospore Preparation	170
К	Interpretation of Zone of Inbihition of the different Antifungal agents.	171



K2	Antifungal sensitivity Pattern of <i>Candida</i> species	172
K3	Susceptibility Profile of different specimens to six Antifungal drugs.	181
K4	Antifungal Sensitivity Test Preparation	183
L	Lactophenol Cotton Blue Procedure and Interpretation of Result (Fungi Staining)	184
L2	Lactophenol Cotton Blue stain	185
М	Gram Stain Procedure	186
N	CHROMagar Candida Procedure and Interpretation of Results	187
N2	CHROMagar picture	189
0	<i>Candida</i> species (Pure Cultures) in Sabouraud Dextrose Agar Medium	190
O2	<i>Candida</i> species (Pure Cultures) in Sabouraud Dextrose Agar Medium	191
Р	API Candida Procedure	192
P2	Reading Table of API Candida	196
P3	API Candida Pictures	197
Q	Statistics	198

LIST OF APPENDIX TABLES

APPENDIX		PAGE
1	<i>Candida species</i> isolated from Out-patient private Physician's clinic turned positive to GGT.	157
2	<i>Candida species</i> isolated from Out-patient private Physician's clinic turned positive to GGT.	159
3	Candida species isolated from OPD turned Positive to GTT.	161
4	Candida species isolated from Out-patient physician's Clinic turned positive to Chlamydospores.	164
5	<i>Candida species</i> isolated from Out-patient physician's Clinic turned positive to Chlamydospores.	166
6	<i>Candida species</i> isolated from OPD turned positive to Chlamydospores.	168
7	Zone of inhibition characterized by the different Antifungal agents.	171
8	Antifungal sensitivity pattern of C. parapsilosis	172
9	Antifungal sensitivity pattern of C. tropicalis	173
10	Antifungal sensitivity pattern of C. krusei	174
11	Antifungal sensitivity pattern of C. krusei	176
12	Antifungal sensitivity pattern of C. albicans	177
13	Antifungal sensitivity of <i>C. albicans</i>	179

14	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Amphotericin-B.	181
15	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Griseofulvin	181
16	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Sporonox	181
17	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Nizoral	182
18	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Diflucan	182
19	Susceptibility profile of <i>Candida</i> species isolated from different specimens to Nystatin	182
20	Reading table of API Candida	196
21	Distribution of <i>Candida</i> species by age group patients of De La Salle University Medical Center (n=32).	198
22	Distribution of <i>Candida</i> species within the civil status of the reproductive age women from De La Salle University Medical Center (n=32).	198
23	Distribution of <i>Candida</i> species within groups of women with or without siblings (n=32).	198
24	Distribution of <i>Candida</i> species among the respondents With clinical presentation related to VVC (n=32)	199
25	<i>Candida</i> species isolated from patients with social history (n=32).	199
26	<i>Candida</i> species isolated from patients with social history (n=32).	199
27	<i>Candida</i> species isolated from patients with social history (n=32).	200
	_	

Page 22 of 213

28	<i>Candida</i> species isolated from patients with social history (n=32).	200
29	<i>Candida</i> species isolated from patients with social history (n=32).	200
30	Frequency distribution of <i>Candida</i> species according to menstrual history of women (n=32).	201
31	Frequency distribution of <i>Candida</i> species among patients who use contraceptive methods (n=32).	201
32	Distribution of <i>Candida</i> species among patients with VVC.	202
33	Susceptibility, intermediate and resistance profile of <i>Candida albicans</i> to six antifungal drugs.	202
34	Susceptibility, intermediate and resistance profile of <i>Candida krusei</i> to six antifungal drugs.	203
35	Susceptibility, intermediate and resistance profile of <i>Candida parapsilosis</i> to six antifungal drugs.	203
36	Susceptibility, intermediate and resistance profile of <i>Candida tropicalis</i> to six antifungal drugs.	204

De La Salle University - Dasmariñas × **GRADUATE PROGRAM** LIST OF APPENDIX FIGURES APPENDIX PAGE 1 Chlamydospores Preparation 170 2 Antifungal Sensitivity Test Preparation 183 Candida species seen under H.P.O. using 3 Lactophenol Cotton Blue stain 185 Different Candida species identified by CHROMagar 4 Candida 189 Candida species (Pure Cultures) in Saborauds 5 Dextrose Agar. 190 Candida species (Pure Cultures) in Saborauds 6 Dextrose Agar. 191

API Candida pictures

7

Page 24 of 213

197